# EVE TRIAL , ALMA SYSTAM

> **NCT06646653** · PHASE3 · RECRUITING · sponsor: **ResQ Medical Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Postpartum Haemorrhage (PPH)
- PPH
- Postpartum Hemorrhage (Primary)

## Interventions

- **DEVICE:** Alma System

## Key facts

- **NCT ID:** NCT06646653
- **Lead sponsor:** ResQ Medical Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-11
- **Primary completion:** 2027-01
- **Final completion:** 2027-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646653, "EVE TRIAL , ALMA SYSTAM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06646653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*